文献速递认知障碍与痴呆帕金森病与运动障碍

微管稳定剂TPI-287多剂量递增在阿尔茨海默病、进行性核上性麻痹和皮质基底节综合征中的反应:一项随机临床试验

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2020-01-01

该研究为在阿尔茨海默病(AD)和4重复tau蛋白病(4RT,包括进行性核上性麻痹PSP和皮质基底节综合征CBS)中开展的两项平行设计、双盲、安慰剂对照的1期随机临床试验,共纳入68例受试者(AD 26例,4RT 42例),评估TPI-287的安全性、耐受性和药效动力学。结果显示AD患者出现过敏样反应,最大耐受剂量为6.3 mg/m2,而4RT为20.0 mg/m2;4RT组跌倒更多且痴呆症状剂量相关恶化,但脑脊液YKL-40水平下降。

要点

  • TPI-287在AD患者中因过敏样反应耐受性较差,最大耐受剂量为6.3 mg/m2。
  • 4RT患者最大耐受剂量为20.0 mg/m2,但观察到更多跌倒和痴呆症状恶化。
  • 尽管脑脊液未检出TPI-287,4RT组脑脊液YKL-40水平较安慰剂组下降。

核心结论

  • TPI-287在AD患者中因过敏样反应耐受性低于4RT患者。
  • 不同tau蛋白病综合征对tau治疗反应不同,提示篮式试验可用于tau治疗早期临床开发。

研究设计与样本

  • 两项平行设计、双盲、安慰剂对照的1期随机临床试验,在AD和4RT中进行。
  • 共筛查94例临床诊断AD(n=39)和4RT(n=55)患者,最终纳入29例AD、14例PSP和30例β-淀粉样蛋白阴性CBS。
  • 随机分组为药物与安慰剂8:3,依次接受2.0、6.3或20.0 mg/m2静脉TPI-287,每3周一次,共9周,可选6周开放标签延伸。
  • 主要终点为安全性和耐受性(最大耐受剂量)。
  • 改良意向治疗分析纳入68例参与者(AD 26例,4RT 42例)。

主要发现

  • AD患者中发生3例严重过敏样反应,4RT患者中未见。
  • AD最大耐受剂量为6.3 mg/m2,4RT为20.0 mg/m2。
  • 4RT组跌倒更多(安慰剂组3例 vs TPI-287组11例)。

临床怎么用

  • TPI-287在AD患者中需警惕过敏样反应,最大耐受剂量较低。
  • 在4RT患者中虽可耐受较高剂量,但需监测跌倒和痴呆症状恶化。
  • 脑脊液YKL-40可能作为tau治疗药效动力学标志物,但需进一步验证。

局限性

  • 1期临床试验样本量较小,主要评估安全性和耐受性。
  • 开放标签延伸部分可能引入偏倚。
  • 脑脊液未检出TPI-287,药物中枢暴露不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease. OBJECTIVE: To assess the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease (AD) or the 4-repeat tauopathies (4RT) progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). DESIGN, SETTING, AND PARTICIPANTS: Two parallel-design, double-blind, placebo-controlled phase 1 randomized clinical trials in AD and 4RT were conducted from December 20, 2013, through May 4, 2017, at the University of California, San Francisco, and University of Alabama at Birmingham. A total of 94 patients with clinically diagnosed AD (n = 39) and 4RT (n = 55) were screened; of these, 3 refused to participate, and 10 with AD and 11 with 4RT did not meet inclusion criteria. A total of 29 patients with AD, 14 with PSP, and 30 with β-amyloid-negative CBS (determined on positron emission tomography findings) were enrolled. Data were analyzed from December 20, 2013, through May 4, 2017, based on modified intention to treat. INTERVENTIONS: Randomization was 8:3 drug to placebo in 3 sequential dose cohorts receiving 2.0, 6.3, or 20.0 mg/m2 of intravenous TPI-287 once every 3 weeks for 9 weeks, with an optional 6-week open-label extension. MAIN OUTCOMES AND MEASURES: Primary end points were safety and tolerability (maximal tolerated dose) of TPI-287. Secondary and exploratory end points included TPI-287 levels in cerebrospinal fluid (CSF) and changes on biomarker, clinical, and neuropsychology measures. RESULTS: A total of 68 participants (38 men [56%]; median age, 65 [range, 50-85] years) were included in the modified intention-to-treat analysis, of whom 26 had AD (14 women [54%]; median age, 63 [range, 50-76] years), and 42 had 4RT (16 women [38%]; median age, 69 [range, 54-83] years). Three severe anaphylactoid reactions occurred in TPI-287-treated patients with AD, whereas none were seen in patients with 4RT, leading to a maximal tolerated dose of 6.3 mg/m2 for AD and 20.0 mg/m2 for 4RT. More falls (3 in the placebo group vs 11 in the TPI-287 group) and a dose-related worsening of dementia symptoms (mean [SD] in the CDR plus NACC FTLD-SB [Clinical Dementia Rating scale sum of boxes with frontotemporal dementia measures], 0.5 [1.8] in the placebo group vs 0.7 [1.6] in the TPI-287 group; median difference, 1.5 [95% CI, 0-2.5]; P = .03) were seen in patients with 4RT. Despite undetectable TPI-287 levels in CSF, CSF biomarkers demonstrated decreased chitinase-3-like protein-1 (YKL-40) levels in the 4RT treatment arm (mean [SD], -8.4 [26.0] ng/mL) compared with placebo (mean [SD], 10.4 [42.3] ng/mL; median difference, -14.6 [95% CI, -30.0 to 0.2] ng/mL; P = .048, Mann-Whitney test). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, TPI-287 was less tolerated in patients with AD than in those with 4RT owing to the presence of anaphylactoid reactions. The ability to reveal different tau therapeutic effects in various tauopathy syndromes suggests that basket trials are a valuable approach to tau therapeutic early clinical development. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT019666666 and NCT02133846.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Tsai RM, Miller Z, Koestler M, et al. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 31710340. doi:10.1001/jamaneurol.2019.3812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。